Thus, we wanted to explore a combination regimen to further enhance the antitumor activity and improve the safety and tolerability of pyrotinib in advanced NSCLC patients with HER2 exon 20 insertions. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.